Massachusetts Financial Services Co. MA Makes New Investment in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Massachusetts Financial Services Co. MA acquired a new position in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGRFree Report) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 114,431 shares of the company’s stock, valued at approximately $887,000.

A number of other institutional investors also recently made changes to their positions in the company. Ritholtz Wealth Management acquired a new stake in shares of Voyager Therapeutics in the third quarter valued at approximately $137,000. WINTON GROUP Ltd acquired a new stake in shares of Voyager Therapeutics in the second quarter valued at approximately $279,000. TD Asset Management Inc raised its position in shares of Voyager Therapeutics by 22.9% in the second quarter. TD Asset Management Inc now owns 66,751 shares of the company’s stock valued at $764,000 after buying an additional 12,451 shares in the last quarter. American International Group Inc. acquired a new stake in shares of Voyager Therapeutics in the second quarter valued at approximately $175,000. Finally, Bank of New York Mellon Corp raised its position in shares of Voyager Therapeutics by 94.4% in the second quarter. Bank of New York Mellon Corp now owns 191,414 shares of the company’s stock valued at $2,192,000 after buying an additional 92,926 shares in the last quarter. Institutional investors own 58.81% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on VYGR shares. StockNews.com upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, January 3rd. Wells Fargo & Company upgraded shares of Voyager Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $9.00 to $14.00 in a research report on Tuesday, January 2nd. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $16.00.

Get Our Latest Stock Report on Voyager Therapeutics

Voyager Therapeutics Stock Performance

Shares of NASDAQ:VYGR opened at $7.69 on Tuesday. The company has a fifty day moving average of $8.01 and a 200-day moving average of $7.97. The company has a market capitalization of $338.28 million, a PE ratio of 6.25 and a beta of 0.98. Voyager Therapeutics, Inc. has a 52-week low of $6.06 and a 52-week high of $14.34.

About Voyager Therapeutics

(Free Report)

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of Alzheimer's disease. It also develops VY-FXN01 to treat Friedreich's ataxia; superoxide dismutase 1 gene silencing program for the treatment of amyotrophic lateral sclerosis; and GBA1 gene replacement program to treat Parkinson's disease.

Read More

Want to see what other hedge funds are holding VYGR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Voyager Therapeutics, Inc. (NASDAQ:VYGRFree Report).

Institutional Ownership by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.